GeoVax Stock Higher As Company Highlights MVA Platform For Ebola Threats
All You Need to Know About GeoVax Labs (GOVX) Rating Upgrade to Buy
GeoVax Labs (NASDAQ:GOVX) Shares Up 21.1% – Should You Buy?
GeoVax Labs, Inc. (GOVX) Q3 2025 Earnings Call Transcript
GeoVax Labs (GOVX) Upgraded to Buy: What Does It Mean for the Stock?
GeoVax Labs Revenue Doubles in Q2
GeoVax Labs, Inc. (GOVX) Q2 2025 Earnings Call Transcript
GeoVax Labs, Inc. (GOVX) Q1 2025 Earnings Call Transcript
GeoVax Labs price target lowered to $14 from $18 at D. Boral Capital
GeoVax Labs, Inc. (GOVX) Q4 2024 Earnings Call Transcript
GeoVax Receives Notice of Allowance For Cancer Vaccine Patent
3 Penny Stocks Ready to Break Out in 2025
GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference
GeoVax Labs, Inc. (GOVX) Q3 2024 Earnings Call Transcript
GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update
GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024
GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
GeoVax to Participate in Upcoming Investor Conferences in September
GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market
Should You Buy GeoVax Labs Inc. (GOVX) After Golden Cross?
GeoVax Labs: Is This Micro-Cap Biotech Stock a Boom or a Bust?
GeoVax's stock slides 20% after company raises $8.5 million in stock sale
GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market
WHO Declares Monkeypox Public Emergency: 5 Mpox Stocks to Watch
GeoVax's stock soars 54% to lead rally in companies developing mpox treatments
GeoVax to Present at the Emerging Growth Conference on August 21, 2024
GeoVax Labs, Inc. (GOVX) Q2 2024 Earnings Call Transcript
GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board
GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update
Update: GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review
GeoVax (GOVX) Stock Pops Ahead of July 18 Catalyst
Why Is GeoVax (GOVX) Stock Up 110% Today?
GeoVax Labs, Inc. (GOVX) Q1 2024 Earnings Call Transcript
GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine
GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress
GeoVax to Present at the 36th Annual Roth Conference
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
GeoVax Labs, Inc. (GOVX) Q4 2023 Earnings Call Transcript
GeoVax Reports 2023 Year-End Financial Results and Provides Business Update
GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024
GeoVax to Present at the 2024 BIO CEO & Investor Conference
GeoVax Announces Multiple Patent Issuances and Allowances
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement
GeoVax Appoints Dr. Marc Pipas as Executive Medical Director, Oncology
GeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer Patients
GeoVax Announces Issuance of Malaria Vaccine Patent
GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024
GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and Smallpox
GeoVax to Participate in Upcoming December Investor Events